BIONTECH SE SPON. ADRS 1
Commented by Fabian Lorenz on December 16th, 2021 | 13:41 CET
Shares with top news: Plug Power, BioNTech, Prospect Ridge
Inflation fears and uncertainty about the impact of the Omicron variant on the course of the Corona pandemic are currently driving stock prices. These are very volatile, with a downward tendency. Highflyers such as Plug Power and BioNTech have also corrected significantly. However, there is positive news about both companies. Plug Power reports further cooperation in the USA to reach the medium-term delivery targets, and BioNTech's vaccine protects against severe disease progression at Omicron. The vaccine is in short supply in Germany. There were several pieces of positive news recently from Prospect Ridge Resources. The gold explorer seems to be sitting on a real treasure.
Read
Commented by Fabian Lorenz on December 14th, 2021 | 12:40 CET
BioNTech, Bayer, Ayurcann: From vaccination records to cannabis
The COVID-19 pandemic is dominating the headlines. There is no end in sight to the pandemic. The shares of BioNTech are benefiting from this. The Mainz-based Company has developed the most successful vaccine to date. The blockbuster is likely to remain in demand and generate billions in revenue for BioNTech. Thus, Berenberg sees a price target of USD 400. Health Minister Karl Lauterbach referred to a necessary vaccination rate of over 90% in the ARD program "Anne Will". BioNTech is currently expanding its production capacity. Just like Ayurcann. Because the legalization of cannabis opens the door to a billion-dollar market for the Canadian Company. Bayer also made headlines yesterday - the US Supreme Court is taking a closer look at the glyphosate dispute. That is new food for the gamblers. They have the Bayer share firmly in their grip.
Read
Commented by Stefan Feulner on December 3rd, 2021 | 12:38 CET
BioNTech, Defence Therapeutics, QIAGEN - End in sight?
The federal and state governments have met and decided on a de facto lockdown for the unvaccinated. In the future, only vaccinated and recovered people will be allowed to shop in retail stores. The same applies to cinemas, theaters and restaurants. In addition, the unvaccinated will have to accept contact restrictions. According to the outgoing chancellor, this is an "act of national solidarity" and is necessary to get out of the current difficult situation - hard times, which the Omicron variant has just exacerbated. But according to US strategists, it is precisely the newly emerged mutant that could signal the approaching end of the Corona pandemic.
Read
Commented by Fabian Lorenz on December 2nd, 2021 | 10:37 CET
Megatrend stocks: BioNTech, Plug Power, Memiontec
The world's stock markets have been very nervous in recent days and weeks. Especially with growth stocks, investors need nerves of steel at the moment - the prices are very volatile. In such unsettled times, one can sleep more soundly if one bets on companies that profit from megatrends. If there is also positive company news at the same time, all the better. This scenario is currently the case for hydrogen leader Plug Power and German biotech giant BioNTech. The latter has just reported an important step in the cancer field. But also, the still largely unknown Memiontec, as a specialist for water treatment, benefits from a megatrend and shines with growth and a record order backlog.
Read
Commented by Fabian Lorenz on November 25th, 2021 | 12:44 CET
BioNTech, Valneva, Cardiol Therapeutics: Vaccination boosters also share boosters?
The Corona pandemic has been with us all for a good 18 months now, and there is no end in sight. While the industrialized countries are boosting their vaccines, large parts of the world's population have still not been vaccinated for the first time. That means that shares of manufacturers of vaccines or drugs against COVID-19 will continue to be the focus of investors. Driven by the booster and mandatory vaccination discussions, BioNTech has left the correction behind, and the share is marching towards EUR 300. Drug developer Cardiol Therapeutics should now pick up again after the successful capital increase. In any event, analysts see price potential. Vaccine developer Valneva benefits from the EU order but has not yet recovered from Tuesday's "flash crash".
Read
Commented by Nico Popp on November 24th, 2021 | 12:41 CET
BioNTech, Defence Therapeutics, Novavax: Another step towards vaccination against cancer
In Portugal and Spain, vaccination rates are higher than in Germany. There are various discussions about the reasons for this. One argument is the fact that infant mortality was high in both countries for a long time. Those who still vividly remember the stories of dead or lifelong damaged infants are less likely to think twice when the doctor calls for vaccination. The recent experience with BioNTech and other vaccines could also give a new boost to the willingness to vaccinate. It is, therefore, quite fitting that vaccines against many different diseases are now emerging on the market.
Read
Commented by André Will-Laudien on November 10th, 2021 | 11:25 CET
Pfizer, BioNTech, Water Ways Technologies, Teva Pharma - High-Tech and the Pandemic!
Shortly after the start of the worldwide vaccination campaigns, Israel already showed itself to be the vaccination world champion. This is no coincidence because Israel is a high-tech country and one of the world leaders. The medical infrastructure, in particular, can benefit from this; it is very well developed and, despite the comparatively small size of the state, is considered to be very resilient. The pandemic has nevertheless hit hard on Israel's economy, which previously grew at rates of 3% annually. In 2020, GDP fell by 3.7%, according to the central bank. That things didn't get worse was due to the large government aid packages. These packages increased government debt from 60 to 73% of GDP, which is still low by global standards. We take a look at some exciting technology topics.
Read
Commented by André Will-Laudien on November 8th, 2021 | 12:08 CET
BioNTech, Moderna, Cardiol Therapeutics, Valneva: COVID-19, the vaccination chaos is perfect!
Now the chaos is perfect. According to studies, the preparation from BioNTech/Pfizer is one of the most effective vaccines against the coronavirus. Hundreds of millions of doses have already been administered worldwide. However, the number of COVID infections is currently through the roof. Even those who have been vaccinated twice are likely still not sufficiently protected against infection. There are also unsettling rumors from BioNTech about irregularities in the conduct of studies during the vaccine's approval. Whether it concerns thereby only "rumors" or "provable facts", the capital investors do not care for the time being. They pressed the sell button and thus sent the entire peer group Adhoc into the basement. We take a closer look at the chaos.
Read
Commented by Stefan Feulner on November 5th, 2021 | 11:22 CET
BioNTech, Sativa Wellness, Merck KGaA - Impressive trend
There is no question that vaccine manufacturers are one of the main winners of the Corona pandemic. The recently presented quarterly figures of Pfizer, BioNTech's partner, show this impressively and suggest that the Mainz-based Company will also announce a sales explosion on November 9. Booster vaccinations are likely to continue this trend. Currently, encouraged by legalization, the cannabis industry is also experiencing a new upswing. Be a part of it from the beginning.
Read
Commented by Stefan Feulner on November 3rd, 2021 | 10:16 CET
Valneva, Cardiol Therapeutics, BioNTech - Is the vaccination subscription coming?
The numbers of people infected with Corona have been rising significantly again for weeks. While only about 67% of Germans are fully vaccinated, the pace is slowing noticeably. Meanwhile, the third dose, the so-called "booster" vaccination, has already been started. The Standing Commission on Vaccination (STIKO) has recommended this booster for people aged 70 and over. A decision on whether booster vaccinations should be offered to everyone is likely to be made soon. For vaccine manufacturers, this means recurring revenues.
Read